6 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 3, 3 Phase 4, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 4 | 3 | Completed 3 |
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
Follow mebeverine: new trials by email Literature Review of mebeverine trials Research Report on mebeverine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ebastine Versus Mebeverine in IBS Patients Ebastine, Duspatalin - IBS - Irritable Bowel Syndrome, IBS | Phase 3 | Active not recruiting | Guy Boeckxstaens | 200 | 2023-03-30 | 2026-09-11 |
| To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea Rifaximin 550 MG, Mebeverine 135 MG, Psyllium Husk - Irritable Bowel Syndrome With Diarrhea | Phase 4 | Completed | Bahria University | 162 | 2023-01-03 | 2023-07-27 |
| The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) alverine-citrate + simethicone and lactase, alverin-citrate + simethicone with placebo - Irritable Bowel Syndrome, Lactose Intolerance | Not applicable | Not yet recruiting | University of Pecs | 200 | 2022-09-01 | 2021-10-29 |
| Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders Mebeverine+Simethicone, Mebeverine, Simethicone - Functional Bowel Disorder | Phase 3 | Completed | Abbott | 465 | 2020-11-27 | 2025-09-16 |
| Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome pentoxyifylline, Mebeverine, ethosuximide - IBS - Irritable Bowel Syndrome | Phase 3 | Recruiting | Tanta University | 60 | 2019-11-01 | 2020-01-03 |
| Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening., Placebo - Incontinence, Urinary Incontinence | Not applicable | Completed | Mansoura University | 120 | 2019-03-01 | 2020-11-19 |
| Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders Coloverin, Placebo - Oncology, Incontinence | Phase 4 | Completed | Mansoura University | 110 | 2017-05-15 | 2020-06-30 |
| Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm Mebeverine - Post-cholecystectomy Gastrointestinal Spasms | Completed | Abbott | 220 | 2015-07-01 | 2019-06-06 | |
| Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial) mebeverine, methylcellulose, placebo - Irritable Bowel Syndrome | Phase 4 | Completed | Hazel Everitt | 135 | 2010-04-01 | 2021-04-30 |
Irritable Bowel Syndrome (5) · Abdominal Pain (2) · Urinary Bladder Neoplasms (2) · Diarrhea (1) · Diurnal Enuresis (1) · Dyspepsia (1) · Flatulence (1) · Lactose Intolerance (1) · Neoplasms (1) · Nocturnal Enuresis (1) · Urinary Incontinence (1)
Abbott (2) · Mansoura University (2) · Bahria University (1) · Guy Boeckxstaens (1) · Hazel Everitt (1) · Tanta University (1) · University of Pecs (1)
Egypt (3) · Russia (2) · Belgium (1) · Hungary (1) · Pakistan (1) · United Kingdom (1)
Ahmed Elhussein, MBBCH (1) · Ahmed Elkarta, MBBCH (1) · Ahmed Mosbah, MD (1) · Guy Boeckxstaens, prof. dr. (1) · Hassan Abol-Enein, MD (1) · Hazel A Everitt, MBChB (1) · Mohamed Soltan, MBBCH (1) · Rashid Ali (1) · Sahar El-Haggar, Prof (1) · Sahar Hegazy, Prof. (1) · Sherief Abd-Elsalam, Ass. Prof. (1) · Tatiana Vladimirova, MD, PhD (1)
PMID 21087463, PMID 23602047, PMID 27144617, PMID 34726293, PMID 35221706
2009 (1)